Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Rupee pushes the Indian mkts into red
Wed, 31 Jul 09:30 am

Barring China (up 0.6%) and Hong Kong (up 0.2%), the other major Asian stock markets have opened the day with losses. Stock markets in Malaysia (down 1%), and Indonesia (down 0.9%) are leading the pack of losers. The Indian equity markets indices have also opened the day in the red. Stocks in the realty and metal space are leading the losses. However, information technology stocks are trading firm.

The Sensex today is down by around 118 points (0.6%), while the NSE-Nifty is down by around 70 points (1.2%). Mid and small cap stocks are also trading in the red with the BSE Mid Cap and BSE Small Cap indices down by around 1.1% and 0.5% respectively. The rupee is trading at Rs 61.11 to the US dollar.

Majority of the pharma companies are trading in red, with Dishman Pharma and Elder pharma leading the pack of losers. Dr Reddy's has announced its results for the quarter ended June 2013. Net sales of the company grew by 12% YoY led by growth in export formulations. In the export formulations, North America witnessed a growth of 37% YoY on the back of low competition launches done during the quarter. However, the domestic segment and the PSAI (Pharmaceuticals service and active ingredients) segment witnessed flat and 6% YoY growth respectively during the quarter. Operating margins declined by 0.7% YoY to 19% due to increase in operating expenses. Bottom line grew by 7% YoY due to the surge in taxes. Taxes increased by 45% YoY during the quarter. Dr Reddy's was trading down by 0.3%.

Banking stocks have opened the day on a negative note with Karur Vysya Bank and IndusInd Bank leading the losses. ING Vysya has reported its first quarter results for the financial year 2013-2014 (1QFY14). The bank reported an increase of 24% YoY in net interest income during the quarter. This was mainly due to a 13% YoY growth in advances. The net interest margin improved to 3.6% in 1QFY14 as compared to 3.4% in 1QFY13. The cost to income ratio declined to 52% during the quarter as compared to 56% seen during the same time last year. Despite the substantial increase in provisioning costs, the bottom line increased by 35% YoY. The capital adequacy ratio stood at 12.6% at the end of June 2013 as against 13.2% in March 2013.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Rupee pushes the Indian mkts into red". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.